MedPath

NEUROVERSION, INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Effect of Stellate Ganglion Block on ME/CFS

Phase 1
Completed
Conditions
Encephalomyelitis, Myalgic
Chronic Fatigue Syndrome
Chronic Fatigue Disorder
Chronic Fatigue and Immune Dysfunction Syndrome
Myalgic Encephalomyelitis
Postviral Fatigue Syndrome
Systemic Exertion Intolerance Disease
Infectious Mononucleosis-Like Syndrome, Chronic
Chronic Fatigue-Fibromyalgia Syndrome
Interventions
First Posted Date
2022-12-27
Last Posted Date
2024-12-06
Lead Sponsor
Neuroversion, Inc.
Target Recruit Count
10
Registration Number
NCT05664711
Locations
🇺🇸

Neuroversion, Anchorage, Alaska, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.